FDMT Insider Jacob Chacko Buys 50,000 Shares

Jacob Chacko, a notable insider, recently purchased 50,000 shares of 4D Molecular Therapeutics, Inc. (NasdaqGS: FDMT) on June 17, 2026. The stock was trading at $9.42 at the time of the transaction.

Insider Buying and Selling at 4D Molecular Therapeutics, Inc.

On June 17, 2026, several insiders, including Jacob Chacko, acquired shares of 4D Molecular Therapeutics. Each insider bought 50,000 shares except for John Milligan, who bought 75,000 shares. These transactions were not part of a pre-planned trading program.

Other Institutional Activity in 4D Molecular Therapeutics

Janus Henderson Group PLC added 611,276 shares of 4D Molecular Therapeutics, bringing its total to 5,247,151 shares valued at about $48.9 million. Meanwhile, RA Capital Management reduced its position by 603,432 shares, holding 5,049,779 shares worth approximately $47 million. Goldman Sachs Group slightly trimmed its stake by 97,467 shares to 4,205,438, valued at $39.2 million. BlackRock, Inc. increased its holdings by 80,427 shares, totaling 4,145,303 shares valued at $38.6 million. Novo Holdings A/S maintained its position with 3,650,737 shares valued at $33.9 million.

4D Molecular Therapeutics, Inc. Stock Down 36.5%

Shares of 4D Molecular Therapeutics currently trade around $9.42. The company has a market cap of approximately $505 million and a forward P/E ratio of -2.59, indicating it is not profitable. The stock's beta is 2.756, suggesting higher volatility compared to the market. Over the past year, the stock has traded between $3.68 and $12.34. Its 50-day moving average is $9.43, and the 200-day moving average is $9.24. The company has a strong current ratio of 9.34 and a quick ratio of 9.01, with a debt-to-equity ratio of 4.55.

Recent Earnings

4D Molecular Therapeutics reported revenue of $88.2 million, reflecting a substantial growth of 216.6%. However, the company posted a net margin of -182.3% and a return on equity of -34.9%, indicating financial challenges. The next earnings report is scheduled for August 10, 2026.

Analysts Set New Price Targets

On March 30, 2026, Jefferies assumed coverage with a 'buy' rating and a $21 price target. HC Wainwright & Co. reiterated its 'buy' rating with a $36 target on March 20, 2026. RBC Capital maintained its 'buy' rating with a $35 target on March 19, 2026. Analysts have a consensus 'buy' recommendation with a mean target price of $28.22, based on 9 opinions.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc. is a biotechnology company focused on developing adeno-associated virus vectors. Its key product, 4D-150, aims to treat retinal diseases like wet age-related macular degeneration through sustained anti-VEGF production. The company is also working on treatments for cystic fibrosis and alpha-1 anti-trypsin deficiency. Headquartered in EmeryVille, California, and led by CEO Dr. David H. Kirn, the company employs 196 people.

Bottom Line

Jacob Chacko's purchase of 50,000 shares of 4D Molecular Therapeutics highlights insider confidence in the company's potential. With a volatile stock history and significant institutional interest, investors keep a close eye on developments. Analyst ratings remain positive, with several firms maintaining 'buy' recommendations and setting high price targets. As always, it's important to remember that insider transactions can be influenced by various factors and don't necessarily indicate immediate stock performance.